These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8725560)

  • 81. Plasminogen activator inhibitors.
    Sprengers ED; Kluft C
    Blood; 1987 Feb; 69(2):381-7. PubMed ID: 3099859
    [No Abstract]   [Full Text] [Related]  

  • 82. In vitro stimulation of plasminogen activator release from vein walls by adrenaline.
    Kjaeldgaard A; Kjaeldgaard M
    J Clin Pathol; 1986 Nov; 39(11):1241-4. PubMed ID: 3098801
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction.
    Hamsten A; de Faire U; Walldius G; Dahlén G; Szamosi A; Landou C; Blombäck M; Wiman B
    Lancet; 1987 Jul; 2(8549):3-9. PubMed ID: 2885513
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Ergometric evaluation of the effects of enalapril maleate in normotensive patients with stable angina.
    Strozzi C; Portaluppi F; Cocco G; Urso L
    Clin Cardiol; 1988 Apr; 11(4):246-9. PubMed ID: 2835195
    [TBL] [Abstract][Full Text] [Related]  

  • 85. The variable effects of angiotensin converting enzyme inhibition on myocardial ischaemia in chronic stable angina.
    Simon J; Gibbs R; Crean PA; Mockus L; Wright C; Sutton GC; Fox KM
    Br Heart J; 1989 Aug; 62(2):112-7. PubMed ID: 2548548
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
    Schleef RR; Higgins DL; Pillemer E; Levitt LJ
    J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Prognosis and management after a first myocardial infarction.
    Moss AJ; Benhorin J
    N Engl J Med; 1990 Mar; 322(11):743-53. PubMed ID: 2407955
    [No Abstract]   [Full Text] [Related]  

  • 88. Elevation of C-reactive protein in "active" coronary artery disease.
    Berk BC; Weintraub WS; Alexander RW
    Am J Cardiol; 1990 Jan; 65(3):168-72. PubMed ID: 2296885
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Effects of benazepril and metoprolol OROS alone and in combination on myocardial ischemia in patients with chronic stable angina.
    Klein WW; Khurmi NS; Eber B; Dusleag J
    J Am Coll Cardiol; 1990 Oct; 16(4):948-56. PubMed ID: 2212376
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Antianginal, hemodynamic and coronary vascular effects of captopril in stable angina pectoris.
    Ikram H; Low CJ; Shirlaw T; Webb CM; Richards AM; Crozier IG
    Am J Cardiol; 1990 Jul; 66(2):164-7. PubMed ID: 2196774
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Influence of metoprolol treatment on sympatho-adrenal activation of fibrinolysis.
    Larsson PT; Wiman B; Olsson G; Angelin B; Hjemdahl P
    Thromb Haemost; 1990 Jun; 63(3):482-7. PubMed ID: 2119530
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma.
    Chandler WL; Trimble SL; Loo SC; Mornin D
    Blood; 1990 Sep; 76(5):930-7. PubMed ID: 2118399
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
    ; Yusuf S; Pitt B; Davis CE; Hood WB; Cohn JN
    N Engl J Med; 1991 Aug; 325(5):293-302. PubMed ID: 2057034
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes.
    Olson JA; Shiverick KT; Ogilvie S; Buhi WC; Raizada MK
    Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1928-32. PubMed ID: 2000398
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies.
    Yarnell JW; Baker IA; Sweetnam PM; Bainton D; O'Brien JR; Whitehead PJ; Elwood PC
    Circulation; 1991 Mar; 83(3):836-44. PubMed ID: 1999035
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effect of captopril, an angiotensin-converting enzyme inhibitor, in patients with angina pectoris and heart failure.
    Cleland JG; Henderson E; McLenachan J; Findlay IN; Dargie HJ
    J Am Coll Cardiol; 1991 Mar; 17(3):733-9. PubMed ID: 1993795
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris.
    Jansson JH; Nilsson TK; Olofsson BO
    Eur Heart J; 1991 Feb; 12(2):157-61. PubMed ID: 1904350
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A lifelong bleeding disorder associated with a deficiency of plasminogen activator inhibitor type 1.
    Diéval J; Nguyen G; Gross S; Delobel J; Kruithof EK
    Blood; 1991 Feb; 77(3):528-32. PubMed ID: 1899347
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Effects of benazepril, a new ACE inhibitor, in effort angina pectoris].
    Lai C; Alberti D; Onnis E; Orani E; Soro A; Pirisi R; Cadeddu M; Lai G; Cherchi A
    Cardiologia; 1991 Oct; 36(10):785-92. PubMed ID: 1799889
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Converting enzyme inhibition in coronary artery disease: a randomized, placebo-controlled trial with benazepril.
    Thürmann P; Odenthal HJ; Rietbrock N
    J Cardiovasc Pharmacol; 1991 May; 17(5):718-23. PubMed ID: 1713985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.